CONFIDENTIAL INFORMATION, INVENTIONS, NON-SOLICITATION AND NON-COMPETITION AGREEMENTConfidentiality Agreement • February 16th, 2022 • Kiromic Biopharma, Inc. • Biological products, (no disgnostic substances) • Texas
In consideration of my employment by Kiromic Biopharma Inc., and its subsidiaries, parents, affiliates, successors and assigns (together, “Kiromic” or the “Company”) and the compensation now and later paid to me, I hereby enter into this Confidential Information, Inventions, Non Solicitation and Non Competition Agreement (the “Agreement”) and agree as follows:
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 16th, 2022 • Kiromic Biopharma, Inc. • Biological products, (no disgnostic substances) • Texas
THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), is effective as of February 14, 2022 (the “Effective Date”) by and between Kiromic Biopharma, Inc., a Delaware corporation (the “Company”), and Dan Clark (the “Executive”). Throughout the remainder of the Agreement, the Company and Executive may be individually referred to as a ‘party” or collectively referred to as “the parties.”
OFFICER INDEMNIFICATION AGREEMENTOfficer Indemnification Agreement • February 16th, 2022 • Kiromic Biopharma, Inc. • Biological products, (no disgnostic substances) • Delaware
This INDEMNIFICATION AGREEMENT (“Agreement”) is made as of February 14, 2022 by and between Kiromic Biopharma, Inc., a Delaware corporation (the “Company”), and Dan Clark (“Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering the subject matter of this Agreement, except this Agreement does not affect any prior agreements regarding the subject matter of this Agreement entered into in connection with Indemnitee’s role as a member of the Company’s Board of Directors (collectively, “Director Indemnification Agreements”), which shall remain in full force and effect pursuant to their terms.
Modification to Employment AgreementEmployment Agreement • February 16th, 2022 • Kiromic Biopharma, Inc. • Biological products, (no disgnostic substances)
Reference is made to your Employment Agreement with Kiromic BioPharma, Inc. (the “Company”) dated January 1, 2020 (the “Employment Agreement”). You and the Company desire to modify certain terms of the Employment Agreement and, accordingly, agree to the following terms and conditions of this modification to the Employment Agreement (this “Modification”), effective as of today, February 9, 2022 (the “Effective Date”):
Corporate Address Fannin South Professional Building, Suite 140 Houston, Texas 77054Transition and Consulting Agreement • February 16th, 2022 • Kiromic Biopharma, Inc. • Biological products, (no disgnostic substances) • Texas
